| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Further information | Following on from information provided to NICE by the company in September 2018, the appraisal of Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378] was suspended from NICE’s work programme. This topic will instead be covered by the NHS England Medicines for Children policy. |
| ID number | 1378 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 February 2023 | Topic selection. Following on from information provided to NICE by the company in September 2018, the appraisal of Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378] was suspended from NICE’s work programme. This topic will instead be covered by the NHS England Medicines for Children policy. |
| 31 May 2018 (14:00) | Scoping workshop (Manchester) |
| 22 March 2018 - 23 April 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we select topics for development, please see our page about topic selection